Keywords: merck, kgaa, erbitux, gets, nice, ok, subset

Merck KGaA's Erbitux gets NICE OK in subset of HNC patients

Article | 30 June 2008

The National Institute for Health and Clinical Excellence (NICE) has recommended Merck KGaA's Erbitux (cetuximab) in combination with radiotherapy for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Merck

Merck KGaA

Go to company listing

Related Drugs

cetuximab

Erbitux

Go to drug listing